Alexza Pharmaceuticals and Ferrer launch Adasuve in Romania Alexza Pharmaceuticals and Ferrer announced that Adasuve inhalation powder, pre-dispensed, is now available in Romania. Ferrer is Alexza's commercial partner for Adasuve in the European Union, Latin America and the Commonwealth of Independent States countries. Adasuve is the first inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder authorized for marketing in the EU.
Alexza Pharmaceuticals initiates Phase 2a study of AZ-002 in epilepsy Alexza Pharmaceuticals has initiated a Phase 2a study of AZ-002 - Staccato alprazolam -, which is being developed for the management of epilepsy in patients with acute repetitive seizures. ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs. Alexza expects to announce results from this study in 1H15.